W. Pronai

Folic acid supplementation improves erythropoietin response.

F. Stockenhuber, K. Silberbauer, M. Riegler-Keil, 1995, Nephron.

EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice

R. Oberbauer, H. Erb, M. Hemetsberger, 2015, Wiener Medizinische Wochenschrift.

Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study

G. Pendl, R. Klauser-Braun, A. Rosenkranz, 2017, Wiener klinische Wochenschrift.

J Am Soc Nephrol 15: 1323–1329, 2004 Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients

R. Kramar, P. Kotanko, G. Sunder-Plassmann, 2022 .

Darbepoetin alfa once every 2 weeks effectively maintained hemoglobin in dialysis patients in an observational study: Austrian cohort of ALTERNATE

A. Rosenkranz, C. Jaeger, U. Barnas, 2014, Wiener Medizinische Wochenschrift.

Extended dosing of darbepoetin alfa in peritoneal dialysis patients

J. D. De Meester, L. McMahon, J. Rottembourg, 2011, BMC nephrology.

Erythropoietin Response to Folic AcidSubstitution

K. Silberbauer, W. Pronai, 1999, Nephron.